Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment

MLA

Yamasaki, Fumiyuki, et al. “Advantages of High B-Value Diffusion-Weighted Imaging to Diagnose Pseudo-Responses in Patients with Recurrent Glioma after Bevacizumab Treatment.” European Journal of Radiology, vol. 81, no. 10, Oct. 2012, pp. 2805–10. EBSCOhost, https://doi.org/10.1016/j.ejrad.2011.10.018.

APA

Yamasaki, F., Kurisu, K., Aoki, T., Yamanaka, M., Kajiwara, Y., Watanabe, Y., Takayasu, T., Akiyama, Y., & Sugiyama, K. (2012). Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment. European Journal of Radiology, 81(10), 2805–2810. https://doi.org/10.1016/j.ejrad.2011.10.018

Chicago

Yamasaki, Fumiyuki, Kaoru Kurisu, Tomokazu Aoki, Masami Yamanaka, Yoshinori Kajiwara, Yosuke Watanabe, Takeshi Takayasu, Yuji Akiyama, and Kazuhiko Sugiyama. 2012. “Advantages of High B-Value Diffusion-Weighted Imaging to Diagnose Pseudo-Responses in Patients with Recurrent Glioma after Bevacizumab Treatment.” European Journal of Radiology 81 (10): 2805–10. doi:10.1016/j.ejrad.2011.10.018.